News

The G.O.O.D. Run results

Results for The G.O.O.D. Run held in Mandaue City, Cebu last March 24, 2013.

AACE-Phil's Marsha Tolentino featured in First Messenger

The First Messenger, the official publication of AACE, recently featured AACE-Phil's Dr. Marsha Tolentino.

AACE-PC BARES ACTIVITIES FOR THYROID AWARENESS MONTH

WHAT do Oprah Winfrey, Kim Atienza and Kelly Osborne have in common? Aside from the fact that all are celebrities, they all have been diagnosed with a thyroid problem.

A G.O.O.D Day for a G.O.O.D Mission

November 17, 2012, Quezon City Hall, 41 specialists, 360 patients…..The American Association of Clinical Endocrinologists Philippines held its annual Endocrine Awareness Day via a medical mission called “A G.O.O.D. Day”.

2012 The G.O.O.D. Run results

The results of the 2012 The G.O.O.D. Run

FDA Advisors Recommend Approval of Obesity Drug Qnexa

February 22, 2012 (Updated February 23, 2012) (Silver Spring, Maryland) — The Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee [1,2] voted overwhelmingly in favor of approving the obesity drug Qnexa (Vivus, Mountain View, CA), a combination of phentermine and controlled-release topiramate

Endocrine Experts Agree with FDA that hCG Diet is Unproven and Potentially Harmful

Chevy Chase, MD— In an effort to provide clarity to the confusion surrounding the human chorionic gonadotropin (hCG) diet, The Hormone Foundation, the public education affiliate of The Endocrine Society, today published, “Myth vs. Fact: The Human Chorionic Gonadotropin (hCG) Diet.” The fact sheet explains how hCG is intended to work in the body and the inherent risks in using hCG to lose weight.

FDA Issues 'Safety Communication' on Fenofibrate

November 9, 2011 (Rockville, Maryland) — The US FDA has issued a safety communication and updated the prescribing information for the cholesterol-lowering agent fenofibric acid (Trilipix, Abbott), stating that the drug may not lower the risk of major cardiovascular events [1]. This is based on data from the ACCORD Lipid trial, in which the combination of fenofibrate plus simvastatin was compared with simvastatin alone in patients with type 2 diabetes mellitus.

FDA HOLDS HEARING ON BISPHOSPHONATES

On Friday, September 9, the United States Food and Drug Administration (FDA) reviewed the long term safety and efficacy of all approved bisphosphonates. Safety concerns discussed included esophageal cancer, osteonecrosis of the jaw (ONJ) and atypical fractures of the femur

USFDA and EMA Drug Safety Communication: Update on Pioglitazone and increased risk of bladder cancer

The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautionssection of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.